Manzillo 1993b.

Methods	Randomised clinical trial.
Participants	Country: Italy. Number randomised: 6. Post‐randomisation dropouts: not stated. Revised sample size: 6. Mean age: not stated. Females: not stated. Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): all participants followed up for 2 months. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: SAMe (n = 3). Further details: SAMe: 1600 mg/day orally for 8 weeks. Group 2: placebo (n = 3).
Outcomes	None of the outcomes of interest reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: although placebo was used, there was no mention of blinding.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: although placebo was used, there was no mention of blinding.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: neither mortality nor adverse events reported.
For‐profit bias	Unclear risk	Comment: information not available.
Other bias	Low risk	Comment: no other bias.